How are myeloma patients with specific genetic features being treated across the United States?
We know that the goal of personalized medicine is to find the best possible treatment for each individual patient. This is particularly important for patients with genetic deletions, additions or translocations. These genetic features can be seen at diagnosis and are commonly acquired over time for a large percentage of patients.
With 80% of patients being seen in the community oncology setting, how are patients with these genetic abnormalities being treated in the real world? Is treatment personalization happening?
Using HealthTree in collaboration with multiple myeloma genomics experts, we will review how patients with specific genetic features are being treated and which treatment combinations are rendering the best outcomes. This will include deletions (del17p, del 1p and del13), gene additions (1q gain) and gene translocations (t(11;14), t(14;16), t(4;14), and t(14;20)).
The study will begin in January 2021 and results will be shared back with participating patients.
Please donate to this important study and consider joining the study if you have any of the above genetic features by FISH. The results will help us better understand optimal treatments for specific genetic features or combinations of features and and how both community oncologists and myeloma specialists are (or are not) customizing therapy.
If you would like to consider joining this and other studies, you can pre-register below.
Donate to the MCRI and genetics study
Did you know that many companies offer a matching gift program to encourage philanthropy among the employees? By simply completing a matching gift form online you may be able to double, or even triple, the impact of your donation! Contributions of any amount help contribute and fund groundbreaking research for high-risk diseases.
Use the search field below to see if your employee participants in the matching gift program. For questions regarding your matching gift, please email email@example.com.
The CrowdCare Foundation (now named the HealthTree Foundation) and Myeloma Crowd is a registered 501(c)3 non-profit, tax ID 45-5354811.
about the author
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of HealthTree Foundation (formerly Myeloma Crowd).